The Menthol Conundrum: Why Banning a Flavor Could Save Lives—and Create a Black Market

Menthol is not just a flavor. It is a pharmacological agent that reduces the harshness of cigarette smoke, suppresses the cough reflex, and alters nicotine metabolism in ways that may increase the addictiveness of cigarettes. These characteristics make menthol cigarettes both more appealing to new smokers (particularly youth, for whom menthol masks the unpleasant sensory experience of first cigarettes) and harder for established smokers to quit (menthol smokers have lower cessation rates than non-menthol smokers, controlling for other factors). The public health case for a menthol ban is strong. But menthol cigarettes are also deeply embedded in the smoking culture of Black Americans—a consequence of decades of targeted marketing by the tobacco industry, which concentrated menthol advertising in Black neighborhoods, sponsored Black cultural events, and positioned menthol brands as part of Black identity. Any menthol ban will have disproportionate effects on Black smokers—effects that could include both public health benefits (increased quitting among Black smokers) and serious unintended consequences (criminal justice enforcement, black market growth, and community distrust of public health institutions).

The racial dimension of menthol cannot be separated from the policy calculus. Approximately 85% of Black smokers use menthol cigarettes, compared to 30% of White smokers. The disparity is not a matter of consumer preference. It is a direct consequence of the tobacco industry's systematic targeting of Black communities over decades—marketing campaigns that positioned menthol brands (Kool, Newport, Salem) as aspirational products within Black culture, distribution strategies that concentrated menthol products in Black neighborhoods, and political donations to Black community organizations that created conflicts of interest and suppressed effective tobacco control advocacy. The menthol ban, if implemented, would disproportionately benefit Black smokers—who would be more likely to quit as a result—but it would also disproportionately affect Black smokers who continue to smoke, who would face either withdrawal from a legal product they've used for decades or pursuit of illicit alternatives. The equity calculus is not simple.

The criminal justice implications are the most contentious aspect of the menthol ban debate. The FDA's proposed rule explicitly states that the ban would apply to manufacturers, distributors, and retailers—not to individual consumers. Possession of menthol cigarettes would not be criminalized. But the experience of other product prohibitions—including the war on drugs—suggests that enforcement inevitably migrates from the supply side to the demand side, particularly in communities of color where policing is already intensive and discretionary. The concern is not that the FDA would arrest individual smokers. It's that local law enforcement would use the ban as a pretext for stops, searches, and citations in Black communities—a pattern documented with marijuana prohibition and other drug laws. The FDA has no control over local law enforcement, and the history of product prohibitions in America is a history of racialized enforcement. The menthol ban cannot be evaluated solely by its intended effects. It must be evaluated by its predictable unintended effects as well.

The black market dimension adds another layer of risk. Menthol cigarettes represent over one-third of the US cigarette market—roughly $30 billion in annual sales. Banning a product of that magnitude does not eliminate the demand for it. It eliminates the legal supply. The demand will migrate to illicit channels: cross-border smuggling from Canada and Mexico (where menthol is legal), domestic illicit manufacturing, and individual resale of legally purchased products from jurisdictions that have not banned menthol (states are not required to follow the federal ban). The size of the menthol black market will depend on the availability of alternatives—both legal alternatives (non-menthol cigarettes, vaping products, nicotine pouches) and enforcement resources. The FDA's enforcement capacity, already stretched by the PMTA process and the synthetic nicotine transition, would be further burdened by a menthol ban. The result would almost certainly be a large, persistent illicit market for menthol cigarettes—with all the attendant consequences: lost tax revenue, organized crime involvement, unregulated product quality, and erosion of respect for law.

The public health calculus depends on uncertain behavioral assumptions. The FDA's modeling estimates that a menthol ban would reduce overall smoking prevalence by approximately 15% within five years, with larger effects among Black smokers, and would prevent approximately 300,000 to 650,000 premature deaths over 40 years. These estimates assume that a significant proportion of menthol smokers would quit rather than switch to non-menthol cigarettes or illicit menthol sources. The experience of jurisdictions that have already banned menthol provides mixed evidence. Canada banned menthol cigarettes at the federal level in 2017; subsequent studies found that approximately 60% of menthol smokers quit or switched to non-menthol cigarettes, while 40% continued using menthol products from illicit sources. Massachusetts, which banned menthol as part of a broader flavor ban in 2020, saw a decline in cigarette sales but also a measurable increase in cross-border purchasing from neighboring states where menthol remained legal. The behavioral response is heterogeneous and context-dependent. The population-level benefits are real but smaller than the most optimistic projections.

The menthol ban debate illustrates a broader tension in public health policy: the tension between the obligation to protect the population from harmful products and the obligation to respect the autonomy of the people who choose to use them—particularly when those people are disproportionately from historically marginalized communities. The public health case for a menthol ban is strong. The equity case is contested. The enforcement case is troubling. The FDA's decision will be evaluated not just by its effect on smoking prevalence, but by whether it reduces or exacerbates the health disparities that are among the most persistent and shameful features of the tobacco epidemic in America. The outcome will depend on implementation details—funding for cessation support in Black communities, explicit protections against criminal enforcement, investment in legal alternatives—that are currently underdeveloped in the FDA's proposed rule. A menthol ban that is implemented without these supports may do more harm than good. A menthol ban that is implemented with them could be among the most consequential public health interventions in a generation.

Shareable insight: Menthol kills—by making cigarettes easier to start and harder to quit—and 85% of Black smokers use menthol products, a direct legacy of industry targeting. But banning a product used by millions of people, in communities with well-founded distrust of government, requires more than a public health justification. It requires an implementation plan that protects the people the ban is intended to help.